Peter M. Glazer, a Yale University researcher, dives into the future of cancer therapy with his groundbreaking work on the 3E10 antibody. He discusses the evolution of monoclonal antibody therapy, emphasizing their ability to target cancer cells more accurately and reduce side effects. Glazer highlights the challenge of reaching cancer-related molecules inside cells, which his innovative 3E10 aims to overcome. The conversation covers the humanization and modification of antibodies to enhance treatment effectiveness, offering hope for improved cancer therapies.
